NeuroBo Pharmaceuticals, Inc. financial data

Symbol
NRBO on Nasdaq
Industry
Pharmaceutical Preparations
Location
545 Concord Avenue, Suite 210, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Gemphire Therapeutics Inc. (to 12/31/2019)
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 284 % -25.8%
Debt-to-equity 54.6 % +53.7%
Return On Equity -189 % -256%
Return On Assets -122 % -212%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.62M shares -77.8%
Common Stock, Shares, Outstanding 8.61M shares -77.6%
Entity Public Float 6.9M USD -1.43%
Common Stock, Value, Issued 9K USD -76.3%
Weighted Average Number of Shares Outstanding, Basic 10.2M shares +101%
Weighted Average Number of Shares Outstanding, Diluted 10.2M shares +101%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 7.53M USD +10.1%
Costs and Expenses 28.9M USD +39.9%
Operating Income (Loss) -28.9M USD -39.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -27.7M USD -134%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -27.7M USD -134%
Earnings Per Share, Basic -4.77 USD/shares +86.1%
Earnings Per Share, Diluted -4.77 USD/shares +86.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 21.7M USD -16.1%
Other Assets, Current 508K USD
Assets, Current 21.9M USD -16.1%
Property, Plant and Equipment, Net 39K USD -4.88%
Operating Lease, Right-of-Use Asset 151K USD -30.7%
Other Assets, Noncurrent 21K USD 0%
Assets 22.1M USD -16.2%
Accounts Payable, Current 1.02M USD -48.7%
Employee-related Liabilities, Current 600K USD +4515%
Accrued Liabilities, Current 3.95M USD +847%
Liabilities, Current 9.11M USD +93%
Operating Lease, Liability, Noncurrent 79K USD -48.4%
Liabilities 9.19M USD +88.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 3K USD -57.1%
Retained Earnings (Accumulated Deficit) -131M USD -26.9%
Stockholders' Equity Attributable to Parent 13M USD -39.9%
Liabilities and Equity 22.1M USD -16.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.44M USD -153%
Net Cash Provided by (Used in) Investing Activities -5K USD -25%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 8.61M shares -77.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 21.7M USD -16.1%
Deferred Tax Assets, Valuation Allowance 7.68M USD +73.4%
Deferred Tax Assets, Gross 7.73M USD +74.5%
Operating Lease, Liability 203K USD
Depreciation 5K USD +400%
Payments to Acquire Property, Plant, and Equipment 5K USD +25%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -27.7M USD -134%
Lessee, Operating Lease, Liability, to be Paid 235K USD
Property, Plant and Equipment, Gross 88K USD
Operating Lease, Liability, Current 75K USD +15.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 89K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 86K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 32K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 60K USD
Deferred Tax Assets, Operating Loss Carryforwards 2.11M USD +469%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 144M USD +15.4%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 50K USD
Share-based Payment Arrangement, Expense 478K USD +40.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%